ACT 2025—Assessments for the 𝘐𝘯 𝘝𝘪𝘷𝘰 Tolerability and Efficacy of a JAK1-siRNA

Presented by Shanté Jackson, Scientist, Study Director, at the ACT Meeting in Phoenix, AZ. 📧 Contact us: https://www.altasciences.com/contact-us#inquiry About Altasciences: Altasciences is an integrated drug development solution company, offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to their preclinical and clinical study needs. From lead candidate selection to proof of concept, we offer a one-stop integrated solution to all your early-phase drug development needs. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements. Altasciences… helping sponsors get better drugs to the people who need them, faster.